News for MyMD Pharmaceuticals, Inc. (MYMD)

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (”œTNFA” or the ”œCompany”), a clinical stage biopharmaceutical company committed to developing novel oral thera

The sarcopenia market size shall grow during the forecast period (2024–2034) due to the launch of upcoming therapies and the increasing cases of...

If you’ve had enough of James Altucher, well, I don’t blame you — he’s one of the more promotional guys out there right now in newsletterland, and his m...

MyMD Pharmaceuticals just reported results for the first quarter of 2024.

MyMD Pharmaceuticals expands preferred stock

MyMD Pharmaceuticals just reported results for the fourth quarter of 2023.

MUNICH, Germany, April 26, 2024 -- Sono Group N.V. , a solar technology company, today announced a correction to its press release issued on April 25, 2024, which provided an update on the...

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free

Discover the top gainers and losers in the healthcare sector, with Acrivon Therapeutics and Vincerx Pharma leading the way.

MyMD Pharmaceuticals stock is rising on Tuesday as MYMD investors react to new amendment to a securities purchase agreement.

Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.

Shares of LumiraDx Limited (NASDAQ: LMDX) fell sharply in pre-market trading after the company agreed to sell its point-of-care technology platform to Roche. LumiraDx shares dipped 19.7% to $0.0517 in pre-market trading. Here are some other stocks moving in pre-market trading.

Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program.

The increasing prevalence of autoimmune disorders, including conditions like Rheumatoid Arthritis, Type I Diabetes, and Addison's Disease, is a key driver...

Shares of ReShape Lifesciences Inc. (NASDAQ: RSLS) rose sharply in pre-market trading after the company said it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX. ReShape Lifesciences shares jumped 44.6% to $0.3630 in pre-market trading.

Time for another longstanding Stock Gumshoe tradition — every Thanksgiving, for 16 years in a row now, we have looked back over our teaser tracking spreadshee...

The emergence of new products in the pipeline will add to the musculoskeletal pain market growth in the future. In addition, persistently rising cases of...

Sjogren's syndrome market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness...

The growing frequency of chronic diseases such as asthma, arthritis, chronic obstructive pulmonary disease (COPD), and others is driving up demand for...